Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
PBM Concerns Induce Surprising Bipartisanship

PBM Concerns Induce Surprising Bipartisanship

May 31, 2023 | Commentary

Recent congressional focus on the business practices of pharmacy benefit managers (PBMs) has been intense. Six committees have held 11 hearings related to PBMs in the first 20 weeks of the 118th Congress, and legislation is advancing in both chambers.

  • Analysis (40)
  • Books (3)
  • Commentary (3)
  • Events (16)
  • Interviews (55)
  • News (54)
  • Op-Eds (82)
  • Press Releases (4)
  • Testimony (20)
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the MediaAugust 11, 2023
  • Congress takes on PBMs
    1 big thing: Congress takes on PBMsAugust 9, 2023
  • Here comes Humira competition
    Here comes Humira competition July 20, 2023
  • Humira Competitors Don’t Guarantee
    Humira Competitors Don’t Guarantee Lower Patient Drug CostsJuly 19, 2023
  • The State of Biosimilars
    The State of Biosimilars: What to WatchJuly 18, 2023
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: Discussing the Latest Inflation ReportJuly 12, 2023
  • Brill discusses adalimumab market
    Alex Brill Interviewed on the Future of the Adalimumab Market June 28, 2023
  • Humira Biosimilars Market Competition
    Taking Stock of the Humira Biosimilars MarketJune 26, 2023
  • squawk box tax proposals
    MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposalsJune 14, 2023
  • Build It in America Act
    Analyzing the Build It in America Act: Proposals for Business Tax ReformJune 12, 2023
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact